TABLE 1.
Patient demographics and baseline disease characteristics
| Characteristic | Patients (N = 113) |
|---|---|
| Age, y | |
| Median (range) | 63 (36, 81) |
| Gender, n (%) | |
| Male | 84 (74) |
| Female | 29 (26) |
| Smoking status, n (%) | |
| Never | 60 (53) |
| Current | 13 (12) |
| Former | 40 (35) |
| ECOG performance at baseline, n (%) | |
| 0 | 53 (47) |
| 1 | 60 (53) |
| Hemoglobin level at baseline, n (%) | |
| <10 g/dL | 18 (16) |
| ≥10 g/dL | 95 (84) |
| Site of primary tumor, n (%) | |
| Urinary bladder | 50 (44) |
| Renal pelvis | 31 (27) |
| Ureter | 24 (21) |
| Urethra | 3 (3) |
| Other | 5 (4) |
| Known metastasis at baseline, n (%) | |
| Visceral metastasis a | 86 (76) |
| Liver metastasis | 27 (24) |
| Lymph node only | 27 (24) |
| Number of prior regimens of anticancer therapies, n (%) | |
| 1 | 69 (61) |
| 2 | 37 (33) |
| ≥3 | 7 (6) |
| Prior platinum‐based therapy, n (%) b | |
| Cisplatin‐based | 85 (75) |
| Carboplatin‐based | 24 (21) |
| Other platinum‐based | 49 (43) |
| Intent of last therapy, n (%) | |
| First line for advanced disease | 73 (65) |
| Second line for advanced disease | 19 (17) |
| Adjuvant | 20 (18) |
| Neoadjuvant | 1 (<1) |
| PD‐L1 expression, n (%) | |
| TC < 50% and IC < 50% | 77 (68) |
| TC ≥ 50% or IC ≥ 50% | 36 (32) |
Abbreviations: IC, immune cell; PD‐L1, programmed death ligand 1; TC, tumor cell.
a
Considered as lung, bone, or any non‐lymph node or soft tissue metastasis.
b
Patients could receive multiple platinum‐based therapies prior to study entry.